Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)

C. Qvortrup, M. Yilmaz, S. Moller, D. Zitnjak, L. Maltha, M. Krogh, L. Noergaard Petersen, F. Hejlesen, S. B. Winther, K. G. Thomsen, P. Pfeiffer

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
Artikelnummer617P
TidsskriftAnnals of Oncology
Vol/bind30
Udgave nummerSuppl. 5
Sider (fra-til)233
ISSN0923-7534
DOI
StatusUdgivet - okt. 2019
Begivenhed44th Congress of the European Society for Medical Oncology - Barcelona, Spanien
Varighed: 27. sep. 20191. okt. 2019

Konference

Konference44th Congress of the European Society for Medical Oncology
LandSpanien
ByBarcelona
Periode27/09/201901/10/2019

Citationsformater